Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Priority Review Voucher Proposal To Be Considered By FDA

Executive Summary

Potential "blockbuster" drugs could receive faster FDA review under a proposed system to encourage development of treatments for neglected diseases

You may also be interested in...



Pfizer, Merck And Sanofi Show Interest In Priority Review Voucher Program

The process for "cashing in" a priority review voucher needs further clarification, three big pharma companies agree

Pfizer, Merck And Sanofi Show Interest In Priority Review Voucher Program

The process for "cashing in" a priority review voucher needs further clarification, three big pharma companies agree

Priority Review “Vouchers” Offered To Firms Developing HIV Drugs In FDA Bill

The Senate's version of FDA user fee reauthorization legislation includes a provision designed to encourage creation of products that treat HIV and other diseases affecting developing countries

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS046965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel